BioSim™ Ipilimumab (Human) ELISA Kit

Ipilimumab is a fully human IgG1κ antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect and maybe through T-cell - mediated anti-tumor immune responses. BioSim™ Ipilimumab ELISA kit has been developed for specific quantification of Ipilimumab concentration in human serum or plasma with high sensitivity and reproducibility.

Alternate Name: CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3, CTLA4

Tag Line: A Sandwich ELISA kit for the quantitative measurement of Ipilimumab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of Ipilimumab in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of Ipilimumab in human serum and plasma

Features & Benefits: Recovery rate: < 100 ± 30% with normal human serum samples with known concentrations Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade®), adalimumab, etanercept, bevacizumab, and trastuzumab Assay Precision: Intra-Assay: CV < 30%; Inter-Assay: CV < 30% (CV (%) = SD/mean X 100) Sensitivity: 30 ng/ml Easy, convenient, sensitive and time-saving method to measure the level of Ipilimumab in human serum and plasma. Detection Range: 30 - 1000 ng/ml